Transthyretin (TTR) stabiliser

Tafamidis

Brand names: Vyndaqel, Vyndamax

Adult dose

Dose: 61mg PO OD (Vyndamax) or 80mg PO OD (Vyndaqel 4×20mg)

Route: PO

Frequency: OD

Clinical pearls

Transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary ATTR polyneuropathy
Specialist amyloid centre per NICE TA984

Contraindications

Pregnancy
Hypersensitivity

Side effects

Diarrhoea
UTI
Headache
Falls

Interactions

BCRP/OAT substrates

Monitoring

Cardiac function
Symptoms

Reference: BNF; NICE TA984; SmPC; https://bnf.nice.org.uk/drugs/tafamidis/. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · Cardiomyopathy
Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · Cardiomyopathy

Drugs

Acoramidis · Transthyretin (TTR) stabiliser

Pathways

Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines